Dade Behring grants sublicense to Abbott for use of PlGF in diagnosis of cardiovascular diseases

By Angela McDaniels

Seattle, Jan. 10 - Dade Behring Inc. said it has granted a non-exclusive sublicense to Abbott Laboratories for the worldwide rights to use placental growth factor (PlGF) in the development of tests for the diagnosis and prognosis of cardiovascular diseases.

A company news release disclosed no additional terms of the agreement.

Originally identified in the placenta, PlGF is now considered to be a primary instigator of atherosclerotic plaque instability, Dade Behring said. It has also been recognized as a predictor for adverse outcomes in patients with known or suspected acute coronary syndrome.

Dade Behring is based in Deerfield, Ill., and manufactures and distributes medical diagnostic instruments and provides maintenance services.

Abbott is based in Abbott Park, Ill., and develops pharmaceuticals and medical device products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.